TNFRSF9 and neoplasm: Other innovative immunotherapy approaches include using agonists of costimulatory molecules such as 4-1BB, OX40, and TLR9 (NCT02554812), developing personalized tumor antigen-based vaccines (NCT02897765 and NCT03289962), and utilizing cytokine mimetics (NCT03520686 and NCT03625323).